Genome & Company's Conversion of 3.1M Preferred Shares to Common Dilutes Existing Shareholders by 6.85%
On July 13, 2026, Genome & Company received a conversion request for 3,099,156 convertible preferred shares into common shares.
The conversion ratio is 1:1, resulting in an equal number of common shares issued, increasing total common shares from 45,255,153 to 48,354,309, a dilution of 6.85%.
This dilution reduces existing shareholders' ownership percentage and may negatively impact earnings per share.
The new common shares are scheduled to be listed on August 10, 2026.
[AI Summary]Genome & Company's conversion of preferred shares to common shares is a simple conversion without additional capital inflow, diluting existing shareholder value by approximately 6.85%, which is moderately negative.
KOSDAQ Filing Information
Other Management Matters (Voluntary Disclosure) (Conversion Request of Convertible Preferred Shares into Common Shares)